(Q35212598)

7 August 2017

1 reference

title

Diagnostic and therapeutic management of cancer of an unknown primary (English)

1 reference

7 August 2017

Pavlidis N

1

1 reference

7 August 2017

Briasoulis E

series ordinal

2

1 reference

7 August 2017

Hainsworth J

series ordinal

3

1 reference

7 August 2017

Greco FA

series ordinal

4

1 reference

7 August 2017

publication date

1 September 2003

1 reference

European Journal of Cancer

7 August 2017

published in

1 reference

7 August 2017

volume

39

1 reference

7 August 2017

issue

14

1 reference

7 August 2017

page(s)

1990-2005

1 reference

Epidemiology of unknown primary tumours

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Adenocarcinoma of unknown primary site. The Brooke Army Medical Center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Metastatic cancer of unknown primary site

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Cancer of unknown primary site

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Unknown primary tumors metastatic to liver

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Undifferentiated carcinoma in young men: the atypical teratoma syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

The Unrecognized Extragonadal Germ Cell Cancer Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Carcinoma of unknown primary: Identification of a treatable subset?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Occult breast carcinoma presenting as axillary metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Peritoneal papillary serous carcinoma with long-term survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Atypical metastasis from prostate cancer. Clinical utility of the immunoperoxidase technique for prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Disseminated prostatic carcinoma simulating primary lung cancer. Indications for immunodiagnostic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Sites of primary malignancies in patients presenting with cerebral metastases. A review of 120 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Brain metastases as the only manifestation of an undetected primary tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Metastatic melanoma of unknown primary

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Specific chromosome change, i(12p), in testicular tumours?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Identifying the primary site in metastatic cancer of unknown origin. Inadequacy of roentgenographic procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Unknown primary adenocarcinoma: incidence of overinvestigation and natural history

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site. A retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Occult breast cancer presenting with axillary metastases. Updated management

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Breast MR imaging in patients with axillary node metastases and unknown primary malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Metastases from Unknown Primary Tumor. PET-FDG as Initial Diagnostic Procedure?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111In-pentetreotide scan.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Evaluation of six tumor markers in patients with carcinoma of unknown primary

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

High serum thyroglobulin levels. Diagnostic indicators in patients with metastases from unknown primary sites

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Metastatic cancer without a detectable primary site

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Secondary carcinoma in cervical lymph nodes with an occult primary tumour. A review of 61 patients including their response to radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Cervical lymph node metastases from carcinoma of undetermined origin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Chemotherapy in the management of metastatic cancer of unknown primary site

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Treatment of the patient with adenocarcinoma of unknown origin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Metastatic carcinomas from occult primary tumors. A study of 254 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Adenocarcinoma of unknown primary site: A clinico-pathological study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Diagnostic persistence in working up metastatic cancer with an unknown primary site

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Prognostic factors in metastatic carcinoma of unknown primary

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. A Hellenic Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Chemotherapy in carcinomas of unknown primary site: a high-dose intensity policy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Phase II trial of cisplatin for adenocarcinoma of unknown primary site. IKZ/IKO Clinical Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Mitomycin C, Epirubicin and Cisplatin versus Mitomycin C Alone as Therapy for Carcinoma of Unknown Primary Origin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen (CFTam)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

A randomized Phase II trial in patients with carcinoma of an unknown primary site

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900547-1

7 January 2021

10.1016/S0959-8049(03)00547-1

Identifiers

DOI

1 reference

7 August 2017

1 reference